JP2018522011A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522011A5
JP2018522011A5 JP2018502129A JP2018502129A JP2018522011A5 JP 2018522011 A5 JP2018522011 A5 JP 2018522011A5 JP 2018502129 A JP2018502129 A JP 2018502129A JP 2018502129 A JP2018502129 A JP 2018502129A JP 2018522011 A5 JP2018522011 A5 JP 2018522011A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
subject
antigen
develop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018502129A
Other languages
English (en)
Japanese (ja)
Other versions
JP7118884B2 (ja
JP2018522011A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/066690 external-priority patent/WO2017012959A1/en
Publication of JP2018522011A publication Critical patent/JP2018522011A/ja
Publication of JP2018522011A5 publication Critical patent/JP2018522011A5/ja
Priority to JP2022107727A priority Critical patent/JP7578646B2/ja
Application granted granted Critical
Publication of JP7118884B2 publication Critical patent/JP7118884B2/ja
Priority to JP2024187654A priority patent/JP2025020198A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018502129A 2015-07-17 2016-07-13 Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物 Active JP7118884B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022107727A JP7578646B2 (ja) 2015-07-17 2022-07-04 Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物
JP2024187654A JP2025020198A (ja) 2015-07-17 2024-10-24 Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306169 2015-07-17
EP15306169.2 2015-07-17
PCT/EP2016/066690 WO2017012959A1 (en) 2015-07-17 2016-07-13 Methods and pharmaceutical compositions for inducing immune tolerance by mucosal vaccination with fc-coupled antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022107727A Division JP7578646B2 (ja) 2015-07-17 2022-07-04 Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物

Publications (3)

Publication Number Publication Date
JP2018522011A JP2018522011A (ja) 2018-08-09
JP2018522011A5 true JP2018522011A5 (enExample) 2019-08-15
JP7118884B2 JP7118884B2 (ja) 2022-08-16

Family

ID=53776517

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018502129A Active JP7118884B2 (ja) 2015-07-17 2016-07-13 Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物
JP2022107727A Active JP7578646B2 (ja) 2015-07-17 2022-07-04 Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物
JP2024187654A Pending JP2025020198A (ja) 2015-07-17 2024-10-24 Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022107727A Active JP7578646B2 (ja) 2015-07-17 2022-07-04 Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物
JP2024187654A Pending JP2025020198A (ja) 2015-07-17 2024-10-24 Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物

Country Status (4)

Country Link
US (3) US10507234B2 (enExample)
EP (1) EP3325004A1 (enExample)
JP (3) JP7118884B2 (enExample)
WO (1) WO2017012959A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6554473B2 (ja) 2013-12-24 2019-07-31 アルゲン−エックス ビーブイビーエー ＦｃＲｎアンタゴニスト及び使用方法
KR20200096786A (ko) * 2017-12-08 2020-08-13 아르제넥스 비브이비에이 전신 중증 근무력증의 치료를 위한 FcRn 길항제의 용도
US12202900B2 (en) 2018-06-08 2025-01-21 argenx BV Compositions and methods for treating immune thrombocytopenia
JP7565951B2 (ja) 2019-06-07 2024-10-11 アルジェニクス ビーブイ 皮下投与に好適なＦｃＲｎインヒビターの医薬製剤
CA3163172A1 (en) 2020-01-08 2021-07-15 Peter Verheesen Methods for treating pemphigus disorders
CN119630697A (zh) 2022-06-15 2025-03-14 阿根思有限公司 Ph依赖性hsa结合分子及使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE238668T1 (de) 1995-01-17 2003-05-15 Brigham & Womens Hospital Rezeptorspezifischer transepithelialer transport von immunogenen
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
WO2003066095A2 (en) 2002-02-07 2003-08-14 Vereniging Voor Christelijk Wetenschappelijk Onderwijs MODULATING TOLERANCE BY MODULATING FcϜRIIB RECEPTOR SIGNALLING
JP5854604B2 (ja) 2007-04-11 2016-02-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｉｇ−ｐＣｏｎｓｅｎｓｕｓ遺伝子ワクチン接種は、自己免疫疾患における抗体依存性の免疫病態から保護する
US9517257B2 (en) * 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9238683B2 (en) 2011-02-23 2016-01-19 University Of Maryland College Park Efficient mucosal vaccination mediated by the neonatal Fc receptor
US20170072032A1 (en) * 2015-07-02 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Prenatal therapy to induce immune tolerance

Similar Documents

Publication Publication Date Title
JP2018522011A5 (enExample)
Al-Halifa et al. Nanoparticle-based vaccines against respiratory viruses
Kuo et al. Neonatal Fc receptor: from immunity to therapeutics
Graham Immunological goals for respiratory syncytial virus vaccine development
Diavatopoulos et al. What is wrong with pertussis vaccine immunity? Why immunological memory to pertussis is failing
JP6595448B2 (ja) 治療効率の増強のために鼻腔内送達する中和抗体に基づく組成物および方法
ES2747760T3 (es) Neutralización de anticuerpos monoclonales humanos contra el antígeno de superficie del virus de la hepatitis B
Henriques et al. Targeting the non-structural protein 1 from dengue virus to a dendritic cell population confers protective immunity to lethal virus challenge
JP2019507113A5 (enExample)
CN113728003A (zh) 重组多克隆蛋白及其使用方法
MY205774A (en) Human il-4r binding antibody, antigen binding fragment thereof, and medical use thereof
JP2018502060A5 (enExample)
HRP20210680T1 (hr) POBOLJŠANA PROTUTIJELA KOJA VEŽU Aβ PROTOFIBRIL
Rainho-Tomko et al. Immunogenicity and protective efficacy of RSV G central conserved domain vaccine with a prefusion nanoparticle
JP2022130681A (ja) Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物
Zhang et al. Immune responses to orally administered recombinant Lactococcus lactis expressing multi-epitope proteins targeting M cells of foot-and-mouth disease virus
Iankov et al. Measles virus expressed Helicobacter pylori neutrophil-activating protein significantly enhances the immunogenicity of poor immunogens
Badillo-Godinez et al. Targeting of rotavirus VP6 to DEC-205 induces protection against the infection in mice
Cacciottolo et al. Nanograms of SARS-CoV-2 spike protein delivered by exosomes induce potent neutralization of both delta and omicron variants
RU2536956C1 (ru) Противовирусное однодоменное мини-антитело, нуклеотидная последовательность, экспрессирующий рекомбинантный вирусный вектор, фармацевтическая композиция и способ профилактики или терапии гриппа типа а
WO2018099968A1 (en) Treatment of infection by respiratory syncytial virus (rsv)
JP2009532361A (ja) Ｉｇｅを標的としたｄｎａワクチン接種
CN116406274A (zh) 用于治疗冠状病毒的cd3抗体
WO2014087849A1 (ja) 粘膜ワクチン用アジュバント
Kumar et al. Preclinical efficacy of a trivalent human FcγRI-targeted adjuvant-free subunit mucosal vaccine against pulmonary pneumococcal infection